目的:观察筋骨草对系膜增生性肾炎(MsPGN)大鼠的治疗作用。方法:采用改良慢性血清病MsPGN模型大鼠,于造模第5周末检测尿蛋白,将尿蛋白阳性者随机分为模型组、雷公藤多苷组、筋骨草组,另设正常对照组。于造模第6周起开始给药,6周后,测定各组大鼠24h尿蛋白定量、血生化,光镜下观察各组大鼠肾组织病理形态学变化。结果:与模型组相比,筋骨草组可显著降低尿蛋白[(24.17±9.15)mg/24h vs (38.91±10.62)mg/24h,P<0.01],且可明显升高TP[(65.67±9.41)g/L vs (51.90±7.32)g/L,P<0.01]、降低BUN[(12.80±1.63)mmol/L vs (15.76±3.57)mmol/L,P<0.05)、Scr[(51.45±6.42)μmol/L vs (63.00±16.79)mmol/L,P<0.05]、TG[(1.75±0.24)mmol/L vs (2.39±0.47)mmol/L,P<0.01]、Tch[(1.69±0.32)mmol/L vs (2.41±0.79)mmol/L,P<0.05],肾组织形态学观察也显示筋骨草组损害减轻,其作用与雷公藤多苷组无统计学差异;此外,筋骨草组的ALT显著低于雷公藤多苷组[(53.08±7.58)U/L vs (83.40±11.53)U/L,P<0.01]。结论:筋骨草对改良的慢性血清病MsPGN大鼠具有较好的治疗作用,与雷公藤多苷相比无明显的肝损害。 Objective: To observe the therapeutic effect of Bugucao on mesangial proliferative glomerulonephritis (MsPGN) in rats. Methods: Urine protein was detected at the end of the 5th week in MsPGN model rats with improved chronic serum disease. Urine protein positive individuals were randomly divided into model group, tripterygium glycosides group, and Radix Astragali group with normal control group. Six weeks after the model was started, six weeks later, the urinary protein excretion and blood biochemistry of the rats in each group were determined. The pathological changes of the kidney were observed under light microscope. Results: Compared with the model group, the Radix Astragali decoction could significantly reduce urinary protein [(24.17 ± 9.15) mg / 24h vs (38.91 ± 10.62) mg / 24h, P <0.01] 9.41) g / L vs 51.90 ± 7.32 g / L, P <0.01], and decreased BUN (12.80 ± 1.63 mmol / L vs 15.76 ± 3.57 mmol / L, P <0.05) (P <0.05), TG [(1.75 ± 0.24) mmol / L vs (2.39 ± 0.47) mmol / L, P <0.01] and Tch [(1.69 ± 0.47) mmol / L vs ± 0.32) mmol / L vs (2.41 ± 0.79) mmol / L, P <0.05]. The morphological observation of kidney also showed that the lesion was alleviated in the Radix Astragalus and the effect was not statistically different from that in the tripterygium glycosides group. In addition, ALT in grass group was significantly lower than that in tripterygium glycosides [(53.08 ± 7.58) U / L vs (83.40 ± 11.53) U / L, P <0.01]. Conclusion: Bugucao has a better therapeutic effect on MsPGN rats with improved chronic serum disease, and no significant liver damage compared with Tripterygium glycosides.